2,3,4,5-Tetramethoxyamphetamine
| Clinical data | |
|---|---|
| Other names | TeMA; TA; 2,3,4,5-TeMA; 2,3,4,5-Tetramethoxyamphetamine; 2,3,4,5-Tetramethoxyphenylisopropylamine; 2-Methoxy-TMA; 2-Methoxy-3,4,5-TMA; 3-Methoxy-TMA-2; 3-Methoxy-2,4,5-TMA |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C13H21NO4 |
| Molar mass | 255.314 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Tetramethoxyamphetamine (TeMA), or 2,3,4,5-tetramethoxyamphetamine (2,3,4,5-TeMA), also known as 2-methoxy-TMA or 3-methoxy-TMA-2, is a drug of the phenethylamine and amphetamine families related to mescaline (3,4,5-trimethoxyphenethylamine).[1][2]
In his book PiHKAL (Phenethylamines I Have Known And Loved), Alexander Shulgin lists TeMA's "probably above 50 mg" orally and its duration as unknown.[1][2] In an earlier publication, it was said to produce threshold effects at a dose of 30 mg orally and long-lived effects at a dose of 50 mg orally.[2] The effects of TeMA have been reported to include disinhibition, intoxication, pupil dilation, and headache.[1][2] It is said to be roughly 6 times as potent as mescaline.[3] TeMA has been said to be the only amphetamine with more than three methoxy groups known to be hallucinogenic.[2] However, the psychedelic properties of TeMA were subsequently questioned.[4]
The chemical synthesis of TeMA has been described.[1]
TeMA was first described in the scientific literature by at least 1975.[3][2] Subsequently, it was described in greater detail by Shulgin in PiHKAL in 1991.[1] The drug is a controlled substance in Canada under phenethylamine blanket-ban language.[5]
See also
- Substituted methoxyphenethylamine
- Tetramethoxyamphetamine
- 2,3,4,5-Tetramethoxyphenethylamine (TeMPEA)
- 2,5-Dimethoxy-3,4-methylenedioxyamphetamine (DMMDA)
- 2-Bromo-TMA
References
- ^ a b c d e Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628. https://www.erowid.org/library/books_online/pihkal/pihkal145.shtml
- ^ a b c d e f Shulgin AT (1978). "Psychotomimetic Drugs: Structure-Activity Relationships". In Iversen LL, Iversen SD, Snyder SH (eds.). Stimulants. Boston, MA: Springer US. pp. 243–333. doi:10.1007/978-1-4757-0510-2_6. ISBN 978-1-4757-0512-6.
3.1.11. 2,3,4,5-Tetramethoxyphenylisopropylamine: Only one substituted phenylisopropylamine with more than three methoxyl groups has been established as being psychotomimetic. This is 2,3,4,5-tetramethoxyphenylisopropylamine (44, 2,3,4,5-tetramethoxyamphetamine). A threshold level of central activity is evident at a 30 mg dose orally, and a relatively long-lived disinhibited intoxication is produced by a 50-mg dosage. Compound (44) has been recorded as having six times the potency of mescaline (Shulgin et ai., 1969), but additional studies will be needed to establish the qualitative nature of its action.
- ^ a b Brimblecombe RW, Pinder RM (1975). "Phenylalkylamines and Their Derivatives". Hallucinogenic Agents. Bristol: Wright-Scientechnica. pp. 55–97.
- ^ Nichols DE (1994). "Medicinal Chemistry and Structure–Activity Relationships". In Cho AK, Segal DS (eds.). Amphetamine and Its Analogs: Psychopharmacology, Toxicology, and Abuse. Academic Press. pp. 3–41. ISBN 978-0-12-173375-9.
Finally, 2,3,4,5-tetramethoxyamphetamine was reported earlier to be active in humans (Shulgin, 1978). However, the more recent description of its effects leaves some doubt about this conclusion (Shulgin and Shulgin, 1991).
- ^ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.